NCT06346184

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

A Randomized, Open Label, Single Dose, Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety After Administration of a Fixed-dose Combination Drug of HCP2303 and Co-administration of RLD2302 and RLD2102 in Healthy Volunteers Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 54 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fasting condition in healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HCP2303	Take 1 tablet once per period
DRUG	RLD2302	Take 1 tablet once per period
DRUG	RLD2102	Take 1 tablet once per period

Timeline

• Start date: 2024-05-02
• Primary completion: 2024-06-10
• Completion: 2024-06-10
• First posted: 2024-04-03
• Last updated: 2024-07-16

Locations

1 site across 1 country: South Korea